Monitoring and maintaining bone health in patients with Turner syndrome

References

• Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 cincinnati international Turner syndrome meeting. Eur J Endocrinol. 2017;177:G1–G70.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Ventura A, Colucci S, et al. Bone fragility in Turner syndrome: mechanisms and prevention strategies. Front Endocrinol. 2016;7:34.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Bondy CA. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008;9:145–151.
   PubMed Web of Science ®Google Scholar
• Zuckerman-Levin N, Yaniv I, Schwartz T, et al. DXA bone mineral density but frail cortical bone in Turner’s syndrome. Clin Endocrinol. 2007;67:60–64.
   PubMed Web of Science ®Google Scholar
• Holroyd CR, Davies JH, Taylor P, et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int. 2010;21:2093–2099.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003;88:5717–5722.
   PubMed Web of Science ®Google Scholar
• Andrade AC, Baron J, Manolagas SC, et al. Hormones and genes of importance in bone physiology and their influence on bone mineralization and growth in Turner syndrome. Horm Res Paediatr. 2010;73:161–165.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Chen ML, Baron J, et al. Bone mineral density and fractures in Turner syndrome. Am J Med. 2003;115:259–264.
   PubMed Web of Science ®Google Scholar
• Wasserman H, Backeljauw PF, Khoury JC, et al. Bone fragility in Turner syndrome: fracture prevalence and risk factors determined by a national patient survey. Clin Endocrinol. 2018;89:46–55.
   PubMed Web of Science ®Google Scholar
• Cardona Attard C, Cameron-Pimblett A, Puri D, et al. Fracture rate in women with oestrogen deficiency. Comparison of Turner syndrome and premature ovarian insufficiency. Clin Endocrinol. 2019;91:743–749.
   PubMed Web of Science ®Google Scholar
• Soucek O, Schonau E, Lebl J, et al. A 6-year follow-up of fracture incidence and volumetric bone mineral density development in girls with Turner syndrome. J Clin Endocrinol Metab. 2018;103:1188–1197.
   PubMed Web of Science ®Google Scholar
• Carrascosa A, Gussinyé M, Terradas P, et al. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. J Bone Miner Res. 2000;15:2005–2010.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–342.
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–192.
   PubMed Web of Science ®Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–850.
   PubMed Web of Science ®Google Scholar
• Bodine PVN, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult Mice. Mol Endocrinol. 2004;18:1222–1237.
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–163.
   PubMed Web of Science ®Google Scholar
• Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96:29–37.
   PubMed Web of Science ®Google Scholar
• Brunetti G, D’Amato G, Chiarito M, et al. An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases. World J Pediatr. 2019;15:4–11.
   PubMed Web of Science ®Google Scholar
• Pasquino AM, Passeri F, Pucarelli I, et al. Spontaneous pubertal development in Turner’s syndrome. Italian study group for Turner’s syndrome. J Clin Endocrinol Metab. 1997;82:1810–1813.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Igarashi Y, Ozono K, et al. Frequencies of spontaneous breast development and spontaneous menarche in Turner syndrome in Japan. Clin Pediatr Endocrinol. 2015;24:167–173.
   PubMedGoogle Scholar
• Faienza MF, Giordani L, Delvecchio M, et al. Clinical, endocrine, and molecular findings in 17β -hydroxysteroid dehydrogenase type 3 deficiency. J Endocrinol Invest. 2008;31:85–91.
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Balsamo A, Giordani L, et al. 17beta-hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence. J Endocrinol Invest. 2009;32:666–670.
   PubMed Web of Science ®Google Scholar
• Cameron-Pimblett A, Davies MC, Burt E, et al. Effects of estrogen therapies on outcomes in Turner syndrome: assessment of induction of puberty and adult estrogen use. J Clin Endocrinol Metab. 2019;104:2820–2826.
   PubMed Web of Science ®Google Scholar
• Nguyen HH, Wong P, Strauss BJ, et al. Delay in estrogen commencement is associated with lower bone mineral density in Turner syndrome. Climacteric. 2017;20:436–441.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tsuburai T, Tokinaga A, et al. Efficacy of estrogen replacement therapy (ERT) on uterine growth and acquisition of bone mass in patients with Turner syndrome. Endocr J. 2015;62:965–970.
   PubMed Web of Science ®Google Scholar
• Högler W, Briody J, Moore B, et al. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J Clin Endocrinol Metab. 2004;89:193–199.
   PubMed Web of Science ®Google Scholar
• Khastgir G, Studd JW, Fox SW, et al. A Longitudinal Study of the Effect of Subcutaneous Estrogen Replacement on Bone in Young Women With Turner’s Syndrome. J Bone Miner Res. 2003;18:925–932.
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Venken K, Ophoff J, et al. Sex steroids and the periosteum–reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006;91:378–382.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Ariyasu D, Izawa M, et al. Gradually increasing ethinyl estradiol for Turner syndrome may produce good final height but not ideal BMD. Endocr J. 2017;64:221–227.
   PubMed Web of Science ®Google Scholar
• Zaiem F, Alahdab F, Al Nofal A, et al. Oral versus transdermal estrogen in Turner syndrome: a systematic review and meta-analysis. Endocr Pract. 2017;23:408–421.
   PubMed Web of Science ®Google Scholar
• Munns CJF, Haase HR, Crowther LM, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89:4130–4135.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Chiarito M, Brunetti G, et al. Growth plate gene involment and isolated short stature. Endocrine. 2020. DOI:10.1007/s12020-020-02362-w
   PubMed Web of Science ®Google Scholar
• Clement-Jones M. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9:695–702.
   PubMed Web of Science ®Google Scholar
• Soucek O, Zapletalova J, Zemkova D, et al. Prepubertal girls with Turner syndrome and children with isolated SHOX deficiency have similar bone geometry at the radius. J Clin Endocrinol Metab. 2013;98:E1241–47.
   PubMed Web of Science ®Google Scholar
• Frederiksen AL, Hansen S, Brixen K, et al. Increased cortical area and thickness in the distal radius in subjects with SHOX-gene mutation. Bone. 2014;69:23–29.
   PubMed Web of Science ®Google Scholar
• McCoy RJ, Widaa A, Watters KM, et al. Orchestrating osteogenic differentiation of mesenchymal stem cells-identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role: mechanoregulation of placental growth factor. Stem Cells. 2013;31:2420–2431.
   PubMed Web of Science ®Google Scholar
• Gerstenfeld LC, Einhorn TA. COX inhibitors and their effects on bone healing. Expert Opin Drug Saf. 2004;6:131-136.
   Google Scholar
• Myers LK, Bhattacharya SD, Herring PA, et al. The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice. Bone. 2006;39:1048–1052.
   PubMed Web of Science ®Google Scholar
• Chen L, Jiang W, Huang J, et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res. 2010;25:2447–2459.
   PubMed Web of Science ®Google Scholar
• Gaur T, Rich L, Lengner CJ, et al. Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol. 2006;208:87–96.
   PubMed Web of Science ®Google Scholar
• Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell. 2006;125:247–260.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Sun L, Kumar TR, et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA. 2006;103:14925–14930.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Finkelstein JS, Ettinger B, et al. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporosis Intern. 2003;14:44–52.
   Google Scholar
• Wang J, Zhang W, Yu C, et al. Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS One. 2015;10:e0134986.
   PubMed Web of Science ®Google Scholar
• Hagen CP, Main KM, Kjaergaard S, et al. FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: longitudinal study of 70 Turner girls with or without spontaneous puberty. Hum Reprod. 2010;25:3134–3141.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Brunetti G, Ventura A, et al. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner’s syndrome. Bone. 2015;81:228–236.
   PubMed Web of Science ®Google Scholar
• Stephure DK. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360–3366.
   PubMed Web of Science ®Google Scholar
• Cleemann L, Holm K, Kobbernagel H, et al. Normal tempo of bone formation in Turner syndrome despite signs of accelerated bone resorption. Horm Res Paediatr. 2011;76:193–201.
   PubMed Web of Science ®Google Scholar
• Nour MA, Burt LA, Perry RJ, et al. Impact of growth hormone on adult bone quality in Turner syndrome: A HR-pQCT study. Calcif Tissue Int. 2016;98:49–59.
   PubMed Web of Science ®Google Scholar
• Gravholt CH, Lauridsen AL, Brixen K, et al. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002;87:2798–2808.
   PubMed Web of Science ®Google Scholar
• Peralta López M, Miras M, Silvano L, et al. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab. 2011;24:307–312.
   PubMed Web of Science ®Google Scholar
• Peralta López M, Centeno V, Miras M, et al. Association of vitamin D receptor gene Cdx2 polymorphism with bone markers in Turner syndrome patients. J Pediatr Endocrinol Metab. 2012;25:669–671.
   PubMed Web of Science ®Google Scholar
• Saggese G, Federico G, Bertelloni S, et al. Mineral metabolism in Turner’s syndrome: evidence for impaired renal vitamin D metabolism and normal osteoblast function. J Clin Endocrinol Metab. 1992;75:998–1001.
   PubMed Web of Science ®Google Scholar
• Evans AL, Paggiosi MA, Eastell R, et al. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res. 2015;30:920–928.
   PubMed Web of Science ®Google Scholar
• Sharma DK, Anderson PH, Morris HA, et al. Visceral fat is a negative determinant of bone health in obese postmenopausal women. Int J Environ Res Public Health. 2020;17:3996.
   Web of Science ®Google Scholar
• Faienza MF, D’Amato G, Chiarito M, et al. Mechanisms involved in childhood obesity-related bone fragility. Front Endocrinol. 2019;10:269.
   PubMed Web of Science ®Google Scholar
• Colaianni G, Brunetti G, Faienza MF, et al. Osteoporosis and obesity: role of Wnt pathway in human and murine models. World J Orthop. 2014;5:242–246.
   PubMedGoogle Scholar
• Mundy GR. Osteoporosis and Inflammation. Nutr Rev. 2008;65:S147–S151.
   Web of Science ®Google Scholar
• Krela-Kaźmierczak I, Szymczak A, Łykowska-Szuber L, et al. Osteoporosis in gastrointestinal diseases. Adv Clin Exp Med. 2016;25:185–190.
   PubMed Web of Science ®Google Scholar
• Aversa T, Messina MF, Mazzanti L, et al. The association with Turner syndrome significantly affects the course of Hashimoto’s thyroiditis in children, irrespective of karyotype. Endocrine. 2015;50:777–782.
   PubMed Web of Science ®Google Scholar
• Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest. 2018;41:99–109.
   PubMed Web of Science ®Google Scholar
• Gordon CM, Leonard MB, Zemel BS. 2013 pediatric position development conference: executive summary and reflections. J Clin Dens. 2014;17:219–224.
   PubMed Web of Science ®Google Scholar
• Soucek O, Schönau E, Lebl J, et al. Artificially low cortical bone mineral density in Turner syndrome is due to the partial volume effect. Osteoporos Int. 2015;26:1213–1218.
   PubMed Web of Science ®Google Scholar
• Baroncelli GI. Quantitative ultrasound methods to assess bone mineral status in children: technical characteristics, performance, and clinical application. Pediatr Res. 2008;63:220–228.
   PubMed Web of Science ®Google Scholar
• Wikiera B, Mierzwicka A, Basiak A, et al. The assessment of skeletal status in young patients with Turner syndrome by 2 densitometric techniques: phalangeal quantitative ultrasound and dual energy X-ray absorptiometry. Adv Clin Exp Med. 2018;27:759–764.
   PubMed Web of Science ®Google Scholar
• Vierucci F, Del Pistoia M, Erba P, et al. Usefulness of phalangeal quantitative ultrasound in identifying reduced bone mineral status and increased fracture risk in adolescents with Turner syndrome. Hormones (Athens). 2014;14:353–360.
   Google Scholar
• Rani S, Bandyopadhyay-Ghosh S, Bandhu Ghosh S, et al. Advances in sensing technologies for monitoring of bone health. Biosensors (Basel). 2020 Apr 21. DOI:10.3390/bios100400422020
   PubMedGoogle Scholar
• Faienza MF, Luce V, Lonero A, et al. Treatment of osteoporosis in children with glucocorticoid-treated diseases. Expert Rev Endocrinol Metab. 2014;9:525–534.
   PubMedGoogle Scholar
• Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int. 2013;2013:250462.
   Web of Science ®Google Scholar
• Faienza MF, Lassandro G, Chiarito M, et al. How physical activity across the lifespan can reduce the impact of bone ageing: a literature review. Int J Environ Res Public Health. 2020;17:1862.
   Google Scholar
• Ross JL, Kushner H, Roeltgen DP. Developmental changes in motor function in girls with Turner syndrome. Ped Neurol. 1996;15:317–322.
   Google Scholar
• Wells GD, O’Gorman CS, Rayner T, et al. Skeletal muscle abnormalities in girls and adolescents with Turner syndrome. J Clin Endocrinol Metab. 2013;98:2521–2527.
   PubMed Web of Science ®Google Scholar
• Soucek O, Matyskova J, Anliker E, et al. The muscle-bone interaction in Turner syndrome. Bone. 2015;74:160–165.
   PubMed Web of Science ®Google Scholar
• Naeraa RW, Brixen K, Hansen RM, et al. Skeletal size and bone mineral content in Turner’s syndrome: relation to karyotype, estrogen treatment, physical fitness, and bone turnover. Calcif Tissue Int. 1991;49:77–83.
   PubMed Web of Science ®Google Scholar
• Shankar RK, Backeljauw PF. Current best practice in the management of Turner syndrome. Ther Adv Endocrinol Metab. 2018;9:33–40.
   PubMed Web of Science ®Google Scholar
• Tsuburai T, Nakamura T, Yoshikata H, et al. Eldecalcitol increases bone mass in patients with Turner syndrome who have insufficient bone mass acquisition after estrogen replacement therapy. Endocr J. 2018;65:629–638.
   PubMed Web of Science ®Google Scholar
• Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011;26:2430–2438.
   PubMed Web of Science ®Google Scholar
• Ruszala A, Wojcik M, Zygmunt-Gorska A, et al. Prepubertal ultra-low-dose estrogen therapy is associated with healthier lipid profile than conventional estrogen replacement for pubertal induction in adolescent girls with Turner syndrome: preliminary results. J Endocrinol Invest. 2017;40:875–879.
   PubMed Web of Science ®Google Scholar
• Beck KL, Anderson MC, Kirk JK. Transdermal estrogens in the changing landscape of hormone replacement therapy. Postgrad Med. 2017;129:632–636.
   PubMed Web of Science ®Google Scholar
• Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents: bisphosphonates in young people. J Paediatr Child Health. 2018;54:223–233.
   PubMed Web of Science ®Google Scholar
• Marini JC. Do bisphosphonates make children’s bones better or brittle? N Engl J Med. 2003;349:423–426.
   PubMed Web of Science ®Google Scholar
• Nasomyont N, Hornung LN, Gordon CM, et al. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Bone. 2019;121:60–67.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Chiarito M, D’amato G, et al. Monoclonal antibodies for treating osteoporosis. Exp Opin Biol Ther. 2018;18:149–157.
   PubMed Web of Science ®Google Scholar
• Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin pharmacokin. 2011;50:793–807.
   Google Scholar
• Boyce AM. Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017;15:283–292.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–420.
   PubMed Web of Science ®Google Scholar
• Bandeira L, Lewiecki EM, Bilezikian JP. Romosozumab for the treatment of osteoporosis. Exp Opin on Biol Ther. 2017;17:255–263.
   PubMed Web of Science ®Google Scholar